BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 2012;63:132-46. [DOI: 10.1016/j.neuropharm.2012.01.017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Bello NT, Walters AL, Verpeut JL, Cunha PP. High-fat diet-induced alterations in the feeding suppression of low-dose nisoxetine, a selective norepinephrine reuptake inhibitor. J Obes 2013;2013:457047. [PMID: 23431425 DOI: 10.1155/2013/457047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
2 Rospond B, Szpigiel J, Sadakierska-chudy A, Filip M. Binge eating in pre-clinical models. Pharmacological Reports 2015;67:504-12. [DOI: 10.1016/j.pharep.2014.11.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
3 Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem 2014;6:1149-65. [PMID: 25078135 DOI: 10.4155/fmc.14.68] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 15.9] [Reference Citation Analysis]
4 Tong T, Yu R, Park T. α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3. Int J Obes (Lond) 2019;43:202-16. [PMID: 30568259 DOI: 10.1038/s41366-018-0176-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017;170:116-47. [PMID: 27773782 DOI: 10.1016/j.pharmthera.2016.10.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 11.5] [Reference Citation Analysis]
6 Kalathiya U, Padariya M, Baginski M. Identification of 1 H -indene-(1,3,5,6)-tetrol derivatives as potent pancreatic lipase inhibitors using molecular docking and molecular dynamics approach: Identification of 1 H -Indene-(1,3,5,6)-tetrol Derivatives. Biotechnology and Applied Biochemistry 2016;63:765-78. [DOI: 10.1002/bab.1432] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Higgins GA, Silenieks LB, Altherr EB, MacMillan C, Fletcher PJ, Pratt WE. Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists. Psychopharmacology (Berl) 2016;233:2841-56. [PMID: 27241709 DOI: 10.1007/s00213-016-4329-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
8 Maniam J, Morris MJ. The link between stress and feeding behaviour. Neuropharmacology. 2012;63:97-110. [PMID: 22710442 DOI: 10.1016/j.neuropharm.2012.04.017] [Cited by in Crossref: 134] [Cited by in F6Publishing: 134] [Article Influence: 13.4] [Reference Citation Analysis]
9 Berglund ED, Liu C, Sohn JW, Liu T, Kim MH, Lee CE, Vianna CR, Williams KW, Xu Y, Elmquist JK. Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis. J Clin Invest 2013;123:5061-70. [PMID: 24177424 DOI: 10.1172/JCI70338] [Cited by in Crossref: 125] [Cited by in F6Publishing: 81] [Article Influence: 13.9] [Reference Citation Analysis]
10 Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, Kopelman P. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet. 2015;385:2521-2533. [PMID: 25703112 DOI: 10.1016/s0140-6736(14)61748-7] [Cited by in Crossref: 210] [Cited by in F6Publishing: 103] [Article Influence: 30.0] [Reference Citation Analysis]
11 Tekola-Ayele F, Doumatey AP, Shriner D, Bentley AR, Chen G, Zhou J, Fasanmade O, Johnson T, Oli J, Okafor G, Eghan BA Jr, Agyenim-Boateng K, Adebamowo C, Amoah A, Acheampong J, Adeyemo A, Rotimi CN. Genome-wide association study identifies African-ancestry specific variants for metabolic syndrome. Mol Genet Metab 2015;116:305-13. [PMID: 26507551 DOI: 10.1016/j.ymgme.2015.10.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
12 Higgins GA, Zeeb FD, Fletcher PJ. Role of impulsivity and reward in the anti-obesity actions of 5-HT 2C receptor agonists. J Psychopharmacol 2017;31:1403-18. [DOI: 10.1177/0269881117735797] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
13 Blechová M, Nagelová V, Žáková L, Demianová Z, Železná B, Maletínská L. New analogs of the CART peptide with anorexigenic potency: The importance of individual disulfide bridges. Peptides 2013;39:138-44. [DOI: 10.1016/j.peptides.2012.09.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
14 De Dios JA, Brass SD. New and unconventional treatments for obstructive sleep apnea. Neurotherapeutics 2012;9:702-9. [PMID: 22987061 DOI: 10.1007/s13311-012-0146-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
15 Bozdag M, Altamimi ASA, Vullo D, Supuran CT, Carta F. State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes. Curr Med Chem 2019;26:2558-73. [PMID: 29932025 DOI: 10.2174/0929867325666180622120625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
16 Bergen WG, Brandebourg TD. Regulation of lipid deposition in farm animals: Parallels between agriculture and human physiology. Exp Biol Med (Maywood) 2016;241:1272-80. [PMID: 27302175 DOI: 10.1177/1535370216654996] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Kim JY, Park HJ, Kim JW, Lee JH, Heo S, Yoon C, Cho S. Development and validation of UPLC and LC-MS/MS methods for the simultaneous determination of anti-obesity drugs in foods and dietary supplements. Arch Pharm Res 2016;39:103-14. [DOI: 10.1007/s12272-015-0665-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Wright FL, Rodgers RJ. On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination. Psychopharmacology 2014;231:787-800. [DOI: 10.1007/s00213-013-3295-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
19 Wright FL, Rodgers RJ. Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. Psychopharmacology (Berl) 2014;231:3729-44. [PMID: 24682505 DOI: 10.1007/s00213-014-3507-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Wright FL, Rodgers RJ. Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. Psychopharmacology (Berl) 2013;228:291-307. [PMID: 23455599 DOI: 10.1007/s00213-013-3036-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
21 Mittapalli GK, Roberts E. Ligands of the neuropeptide Y Y2 receptor. Bioorg Med Chem Lett 2014;24:430-41. [PMID: 24365162 DOI: 10.1016/j.bmcl.2013.11.061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
22 Higgins GA, Fletcher PJ, Shanahan WR. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacology & Therapeutics 2020;205:107417. [DOI: 10.1016/j.pharmthera.2019.107417] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
23 Tao Y, Yuan Z, Xie J. G Protein-Coupled Receptors as Regulators of Energy Homeostasis. G Protein-Coupled Receptors in Energy Homeostasis and Obesity Pathogenesis. Elsevier; 2013. pp. 1-43. [DOI: 10.1016/b978-0-12-386933-3.00001-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Avraham Y, Katzhendler J, Vorobeiv L, Merchavia S, Listman C, Kunkes E, Harfoush F, Salameh S, Ezra AF, Grigoriadis NC, Berry EM, Najajreh Y. Novel Acylethanolamide Derivatives That Modulate Body Weight through Enhancement of Hypothalamic Pro-Opiomelanocortin (POMC) and/or Decreased Neuropeptide Y (NPY). J Med Chem 2013;56:1811-29. [DOI: 10.1021/jm300484d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
25 Rodgers R. Bench to bedside in appetite research: Lost in translation? Neuroscience & Biobehavioral Reviews 2017;76:163-73. [DOI: 10.1016/j.neubiorev.2016.08.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Higgs S, Spetter MS, Thomas JM, Rotshtein P, Lee M, Hallschmid M, Dourish CT. Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies. J Psychopharmacol 2017;31:1460-74. [PMID: 29072515 DOI: 10.1177/0269881117736917] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
27 Milano W, De Biasio V, Di Munzio W, Foggia G, Capasso A. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocr Metab Immune Disord Drug Targets 2020;20:1232-43. [PMID: 32410565 DOI: 10.2174/1871530320666200515112853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci 2013;36:133-40. [PMID: 23312373 DOI: 10.1016/j.tins.2012.12.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
29 Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419-1427. [PMID: 25258511 DOI: 10.2147/dddt.s55587] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
30 An H, Sohn H, Chung S. Phentermine, sibutramine and affective disorders. Clin Psychopharmacol Neurosci 2013;11:7-12. [PMID: 23678348 DOI: 10.9758/cpn.2013.11.1.7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opinion on Therapeutic Patents 2013;23:725-35. [DOI: 10.1517/13543776.2013.790957] [Cited by in Crossref: 185] [Cited by in F6Publishing: 177] [Article Influence: 20.6] [Reference Citation Analysis]
32 Smith SL, Dean RL, Todtenkopf MS, Heal DJ. Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats. J Psychopharmacol 2019;33:383-91. [PMID: 30676189 DOI: 10.1177/0269881118822111] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Dodson MV, Boudina S, Albrecht E, Bucci L, Culver MF, Wei S, Bergen WG, Amaral AJ, Moustaid-moussa N, Poulos S, Hausman GJ. A long journey to effective obesity treatments: is there light at the end of the tunnel? Exp Biol Med (Maywood) 2013;238:491-501. [DOI: 10.1177/1535370213477603] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
34 Thomas JM, Dourish CT, Tomlinson JW, Hassan-smith Z, Higgs S. Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers. Psychopharmacology 2014;231:2449-59. [DOI: 10.1007/s00213-013-3409-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
35 Paspala I, Katsiki N, Kapoukranidou D, Mikhailidis DP, Tsiligiroglou-Fachantidou A. The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity. Open Cardiovasc Med J 2012;6:147-55. [PMID: 23346258 DOI: 10.2174/1874192401206010147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
36 Scotti L, Monteiro AFM, de Oliveira Viana J, Mendonça Junior FJB, Ishiki HM, Tchouboun EN, Santos R, Scotti MT. Multi-Target Drugs Against Metabolic Disorders. Endocr Metab Immune Disord Drug Targets 2019;19:402-18. [PMID: 30556507 DOI: 10.2174/1871530319666181217123357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
37 Yu XX, Watts LM, Manchem VP, Chakravarty K, Monia BP, McCaleb ML, Bhanot S. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS One 2013;8:e66923. [PMID: 23922646 DOI: 10.1371/journal.pone.0066923] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
38 Fan Y, Yang M, Wang Y, Li Y, Zhou Y, Chen X, Shan L, Wei J, Gao C. Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. Drug Development and Industrial Pharmacy 2014;41:801-11. [DOI: 10.3109/03639045.2014.903494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Bergen WG. Peptide-Based Regulation of Metabolism as Related to Obesity. Endocrinology 2017;158:3081-2. [PMID: 28977611 DOI: 10.1210/en.2017-00696] [Reference Citation Analysis]